Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Assertio Holdings, Inc.

Market Cap 152M 131M 120M 113M 213M 14.33B 215M 1.43B 556M 7.03B 570M 558M 24.33B P/E 2026 *
-13.1x
P/E 2027 * 40.5x
Enterprise Value 152M 131M 120M 113M 213M 14.33B 215M 1.43B 556M 7.03B 570M 558M 24.33B EV / Sales 2026 *
1.3x
EV / Sales 2027 * 1.2x
Free-Float
98.03%
Yield 2026 *
-
Yield 2027 * -
1 day+0.09%
1 week+0.09%
Current month+0.26%
1 month+0.77%
3 months+88.00%
6 months+112.52%
Current year+159.10%
1 week 23.48
Extreme 23.48
23.5
1 month 23.36
Extreme 23.36
23.5
Current year 9.11
Extreme 9.11
23.5
1 year 8.61
Extreme 8.61
23.5
3 years 7.71
Extreme 7.7055
96.15
5 years 7.71
Extreme 7.7055
120.15
10 years 7.71
Extreme 7.7055
1,621.19
Director TitleAgeSince
Director/Board Member 26 16/06/2026
Director/Board Member - 16/06/2026
Date Insider Type Main position Quantity % Market Cap.
05-13Don

Chairman

-13,332 0.2069%
05-05Free

Director

4,851 0.0753%
05-05Free

Chairman

4,851 0.0753%
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+0.09%+136.69%-73.80% 152M
-0.94%-2.14%+40.54%+148.38% 1,001B
-0.42%-1.80%+53.69%+42.60% 566B
-0.56%-1.65%+19.27%+59.57% 393B
-1.18%+0.68%+24.66%+16.53% 326B
+1.09%+1.65%+26.61%+33.32% 276B
+1.42%+0.06%+26.36%+14.29% 277B
+1.87%+0.87%-41.49%-48.26% 193B
-1.78%+1.16%+17.79%+48.77% 188B
-1.40%+3.27%+16.16%+59.08% 158B
Average -0.18%+0.66%+32.03%+30.05% 337.7B
Weighted average by Cap. -0.38%-0.36%+29.36%+66.26%

Financials

2026 *2027 *
Net sales 117M 101M 92.56M 87.12M 164M 11.01B 165M 1.1B 427M 5.41B 438M 429M 18.7B 127M 109M 100M 94.53M 178M 11.95B 179M 1.19B 463M 5.86B 475M 465M 20.29B
Net income -11.5M -9.92M -9.12M -8.59M -16.13M -1.09B -16.27M -108M -42.08M -533M -43.16M -42.24M -1.84B 4.35M 3.76M 3.45M 3.25M 6.11M 411M 6.16M 40.93M 15.93M 202M 16.34M 15.99M 698M
Net Debt - -
Logo Assertio Holdings, Inc.
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Employees
53
Date Price Change Volume
15/06/26 23.50 $ +0.09% 274,343
12/06/26 23.48 $ +0.04% 486,525
11/06/26 23.47 $ -0.04% 298,118
10/06/26 23.48 $ +0.09% 439,224
09/06/26 23.46 $ +0.13% 547,036
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
23.50USD
Average target price
24.43USD
Spread / Average Target
+3.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASRT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!